Projected Earnings Date: 2026-02-10    (Delayed quote data   2026-02-10)
Last
 80.47
Change
 ⇑ +2.03   (+2.59%)
Volume
  3,512,745
Open
 78.62
High
 81.05
Low
 78.38
8EMA (Daily)
 79.35
40EMA (Daily)
 79.49
50EMA (Daily)
 79.38
STO (Daily)
 40.116
MACD Hist (Daily)
 -0.038
8EMA (Weekly)
 79.677
40EMA (Weekly)
 81.31
50EMA (Weekly)
 82.03
STO (Weekly)
 74.410
MACD Hist (Weekly)
 0.448
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
optionchance optionchance
Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2026 OptionChance.com